GlassScriptPhysician profile
Elizabeth J Raynor
NPI 1275165581
$12,223.14
in general payments reported to CMS, 2019-2025
45 companies · $3,365 in 2025
The $3,365 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $905 · 2022: $2,498 · 2023: $3,649 · 2024: $1,806 · 2025: $3,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,329 · Travel and Lodging: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,329.41 |
| Travel and Lodging | $1,491.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,094.42 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Superion Indirect Decompression System |
| Abbvie INC. | $1,324.57 | 2021-2025 | |
| Si-Bone, INC. | $1,187.12 | 2022-2025 | |
| Saluda Medical Americas, INC. | $721.39 | 2022-2025 | Evoke Scs, Evoke |
| Collegium Pharmaceutical, INC. | $436.94 | 2021-2025 | Belbuca, Xtampza, Nucynta |
| Medtronic, INC. | $387.75 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Lundbeck LLC | $337.07 | 2021-2025 | Vyepti |
| Merz Pharmaceuticals, LLC | $304.30 | 2022-2025 | Xeomin |
| Virtus Pharmaceuticals LLC | $272.42 | 2023-2025 | Levorphanol Tartrate |
| Allergan, INC. | $268.29 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $259.79 | 2022-2024 | Quviviq |
| Pfizer INC. | $247.24 | 2021-2025 | |
| Lilly USA, LLC | $233.93 | 2021-2025 | Zepbound, Reyvow, Emgality |
| Novo Nordisk INC | $184.40 | 2023-2025 | Wegovy, Saxenda |
| Forte Bio-Pharma LLC | $181.88 | 2021-2025 | Prolate, Nalocet, Tanlor |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.54 | 2021-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $140.33 | 2021-2023 | Ztlido |
| Vertex Pharmaceuticals Incorporated | $116.85 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $103.03 | 2023-2025 | Horizant, Adthyza, Horizant |
| Averitas Pharma INC. | $99.05 | 2023-2025 | Qutenza |
| Impel Pharmaceuticals INC. | $97.04 | 2023 | Trudhesa |
| Arbor Pharmaceuticals, INC. | $91.94 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $78.41 | 2021 | |
| Vertos Medical, INC. | $75.12 | 2021-2023 | Mild Device Kit |
| Teva Pharmaceuticals USA, INC. | $74.23 | 2022-2023 | Ajovy |
| Grt US Holding, INC. | $71.21 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $68.90 | 2022 | |
| Abbott Laboratories | $65.19 | 2023 | Proclaim, Eterna |
| Biohaven Pharmaceuticals, INC. | $63.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $59.16 | 2021 | |
| Almatica Pharma LLC | $58.54 | 2021 | |
| Biotronik Nro, INC. | $52.33 | 2025 | Prospera |
| Amneal Pharmaceuticals LLC | $47.08 | 2023 | Lyvispah |
| Protega Pharmaceutials INC | $32.41 | 2022-2023 | Roxybond |
| Axsome Therapeutics, INC. | $28.34 | 2025 | Symbravo |
| Globus Medical, INC. | $24.54 | 2025 | Senza |
| Stryker Corporation | $24.39 | 2025 | Mild Device Kit |
| Valinor Pharma, LLC | $23.37 | 2024 | Movantik |
| Redhill Biopharma INC. | $23.27 | 2021 | |
| Spinal Simplicity, LLC | $21.65 | 2025 | Ha Minuteman G3-R |
| Bioventus LLC | $21.46 | 2024 | Gelsyn-3 |
| Takeda Pharmaceuticals U.S.A., INC. | $19.23 | 2023 | Trintellix |
| Nalu Medical, INC. | $17.78 | 2025 | Nalu Neurostimulation System |
| International Rehabilitative Sciences, INC | $13.78 | 2025 | Rs-4i Plus With Intersperse |
| Curonix LLC | $13.71 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Raynor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.